Mainz Biomed

MYNZ

Market cap $8.07M

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year.

BERKELEY, Calif. and MAINZ, Germany, Sept.

BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

MYNZ Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.